AEON Biopharma Q3 net income rises, biosimilarity program advances
AEON•AEON Biopharma reported third-quarter net income of $2.47 million, compared with a loss a year earlier, and raised $6.2 million through milestone warrant exercises. The company said FDA feedback helped guide its ABP-450 biosimilarity program and expects to start a pharmacodynamic study in the first quarter of 2027.
1. Earnings and funding
AEON Biopharma reported third-quarter net income of $2.47 million and earnings per share of $0.01. It raised $6.2 million through milestone warrant exercises to fund ABP-450 development and said cash and warrant proceeds are expected to fund operations into the second quarter of 2027.
2. ABP-450 development
The company said an FDA Type 2b meeting provided direction on integrating analytical, pharmacodynamic and clinical evidence for its biosimilarity program. Expanded analytical data showed 98% coverage and 100% identity of the ABP-450 neurotoxin sequence to BOTOX.
3. Study plans
AEON expects to initiate a CMAP pharmacodynamic study for ABP-450 in the first quarter of 2027 and plans a multi-lot forced degradation comparability study in the first half of 2027.




